BC Innovations | Nov 18, 2019
Distillery Therapeutics

Microtubule inhibitors including colchicine for myotonic dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Myotonic dystrophy type 1 (DM1) Colchicine and other microtubule inhibitors could treat DM1, which is caused by expansions of CTG repeats in the DMPK gene. A screen for compounds reducing RNA...
BC Innovations | Aug 1, 2019
Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
BC Innovations | May 3, 2019
Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
BC Extra | Apr 23, 2019
Company News

Fulcrum gets rights to GSK's shelved p38 kinase inhibitor

Following the failure of late-stage trials conducted by GSK in acute coronary syndrome and chronic obstructive pulmonary disease, Fulcrum will seek to revive the pharma's losmapimod for a rare genetic disease with an exclusive, worldwide...
BC Innovations | Jan 3, 2018
Product R&D

Expanding small molecule horizons

With a platform boasting more than a decade of preclinical rigor and $55.3 million in series A funding, Expansion Therapeutics Inc. is the latest company to step into the RNA-binding small molecule arena. The newco...
BC Innovations | Sep 14, 2017
Emerging Company Profile


Two of the outstanding hurdles for CRISPR-based gene editing are the safety concerns of permanently changing the cell’s DNA and the efficacy limitations of relying on natural DNA repair mechanisms to fix the cuts. Locana...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
BC Innovations | Apr 28, 2016

Virtually biotechs

Harvard University 's $20 million licensing deal with Merck & Co. Inc in March for a preclinical cancer therapy brought in more cash in one swoop than the university's tech transfer office saw in all...
BioCentury | Mar 14, 2016
Emerging Company Profile

AMO's CNS ammunition

AMO Pharma Ltd. is in-licensing therapies for rare genetic diseases with no treatment options, starting with two potentially disease-modifying candidates for fragile X syndrome and myotonic dystrophy type 1. The company's first candidate is AMO-01...
BC Week In Review | Sep 1, 2014
Company News

Columbia Laboratories, XenoGesis deal

Columbia Laboratories’ CRO subsidiary, Molecular Profiles Ltd. , partnered with XenoGesis to provide preclinical and formulation development services. XenoGesis will provide expertise in preclinical drug metabolism and pharmacokinetics ( DMPK ) to support Molecular Profiles’ pharmaceutical development services....
Items per page:
1 - 10 of 40